Sefaxersen sodium clinical trials
Also written IONIS-FB-LRx.
A product of Sefaxersen; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses sefaxersen sodium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Sefaxersen
Studies
Open first, then newest update. How each study uses sefaxersen sodium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)CompletedPhase 2Ionis Pharmaceuticals, Inc.NCT03815825Written as IONIS-FB-LRx
- A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT04014335Written as IONIS-FB-LRx
- Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)WithdrawnPhase 2Ionis Pharmaceuticals, Inc.NCT03446144Written as IONIS-FB-Lrx
Codes
What other systems call sefaxersen sodium · ClinicalTrials.gg INT014612
- UNII (FDA) 37KI8XF3IHSEFAXERSEN SODIUMOne source FDA
- NCI Thesaurus C203036Sefaxersen SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 37KI8XF3IH | SEFAXERSEN SODIUM | One source FDA |
| NCI Thesaurus | C203036 | Sefaxersen Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.